This study aims to identify clinical and socioeconomic factors associated with long-term, post-surgical opioid use in the head and neck cancer population.
Methods:
A single center retrospective study was conducted including patients diagnosed with head and neck cancer between January 1, 2014 and July 1, 2019 who underwent primary surgical management. The primary outcome measure was continued opioid use 6 months after treatment completion. Both demographic and cancer-related variables were recorded to determine what factors were associated with prolonged opioid use. Univariate analysis was performed using chi-squared test for categorical variables and 2-sample t-test for continuous variables. Multivariate analysis was performed using logistic regression.
Results:
A total of 359 patients received primary surgical management. Forty-five patients (12.53%) continued to take opioids 6 months after treatment completion. Using univariate analysis, patients less than 65 years of age (P = .0126), adjuvant chemoradiation (n = 25, P < .001), and overall length of hospital stay (8.60 ± 8.58 days, P = .0274) were significantly associated with long term opioid use. Multivariate logistic regression showed that adjuvant chemoradiation (OR = 3.446, 95% CI [1.742, 6.820], P = .0004) and overall length of hospital stay (OR = 0.949, 95% CI [0.903, 0.997], P = .0373) to be significantly associated with opioid use 6 months after head and neck cancer treatment.
Conclusion:
Long-term postoperative opioid use in head and neck cancer patients is significantly associated with adjuvant chemoradiation, and patients with longer length of hospital stay. Therefore, future research should focus on interventions to better manage opioid use during the acute treatment period to decrease long-term use.
RosenblumAMarschLAJosephHPortenoyRK.Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405-416.
6.
WiffenPJWeeBDerrySBellRFMooreRA.Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7:CD012592.
7.
OylerDRDeepKSChangPK.Opioid use in the acute setting: a survey of providers at an academic medical center. J Opioid Manag. 2018;14(3):203-210.
8.
van den Beuken-van EverdingenMHde RijkeJMKesselsAGSchoutenHCvan KleefMPatijnJ.Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437-1449.
9.
ChouRTurnerJADevineEB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health pathways to prevention workshop. Ann Intern Med. 2015;162(4):276-286.
10.
BaldiniAVon KorffMLinEHB. A review of potential adverse effects of long-term opioid therapy. Prim Care Companion CNS Disord. 2012;14(3). PCC.11m01326.
11.
SviderPFArianpourKGuoE, et al. Opioid prescribing patterns among otolaryngologists: crucial insights among the medicare population. Laryngoscope. 2018;128(7):1576-1581.
12.
BrennerMJ.Reaping what we sow-reflections on the otolaryngologist’s role in opioid stewardship. Otolaryngol Head Neck Surg. 2019;145:887-888. doi:10.1001/jamaoto.2019.2192
13.
KwonJHHuiDChisholmGBrueraE.Predictors of long-term opioid treatment among patients who receive chemoradiation for head and neck cancer. Oncologist. 2013;18(6):768-774.
14.
SchumacherLDSargiZBMasforrollM, et al. Long-term opioid use in curative-intent radiotherapy: one-year outcomes in head/neck cancer patients. Head Neck. 2020;42:608-624.
15.
McDermottJDEguchiMStokesWA, et al. Short- and long- term opioid use in patients with oral and oropharynx cancer. Otolaryngol Head Neck Surg. 2019;160(3):409-419.
16.
SilverNDouradoJHitchcockK, et al. Chronic opioid use in patients undergoing treatment for oropharyngeal cancer. Laryngoscope. 2019;129(9):2087-2093.
17.
ZayedSLinCBoldtRG, et al. Risk of chronic opioid use after radiation for head and neck cancer: a systematic review and meta-analysis. Adv Radiat Oncol. 2021;6(2):100583.
18.
El-DeiryMFunkGFNalwaS, et al. Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2005;131(10):879-885.
19.
HootenWMSt SauverJLMcGreeMEJacobsonDJWarnerDO.Incidence and risk factors for progression from short-term to episodic or long-term opioid prescribing: a population-based study. Mayo Clin Proc. 2015;90:850-856.
20.
CalcaterraSLYamashitaTEMinSJKenistonAFrankJWBinswangerIA.Opioid prescribing at hospital discharge contributes to chronic opioid use. J Gen Intern Med. 2016;31:478-485.
21.
CataJPPatinoMGorurA, et al. Persistent and chronic postoperative opioid use in a cohort of patients with oral tongue squamous cell carcinoma. Pain Med. 2020;21(5):1061-1067.
22.
DangSDuffyALiJC, et al. Postoperative opioid-prescribing practices in otolaryngology: a multiphasic study. Laryngoscope. 2020;130:659-665.
23.
PangJTringaleKRTapiaVJ, et al. Chronic opioid use following surgery for oral cavity cancer. Otolaryngol Head Neck Surg. 2017;143(12):1187-1194.
24.
CrakerNCGalTJWellsLSchadlerAPrudenSAouadRK.Chronic opioid use after laryngeal cancer treatment: a va study. Otolaryngol Head Neck Surg. 2020;162(4):492-497.
25.
DaraeiPMooreCE.Racial disparity among the head and neck cancer population. J Cancer Educ. 2015;30(3):546-551.
26.
NoconCCAjmaniGSBhayaniMK.A contemporary analysis of racial disparities in recommended and received treatment for head and neck cancer. Cancer. 2020;126(2):381-389.
27.
JivrajNKRaghavjiFBethellJ, et al. Persistent postoperative opioid use: a systematic literature search of definitions and population-based cohort study. Anesthesiology. 2020;132(6):1528-1539.
28.
BolligCAKinealyBPGilleyDR, et al. Implications of treatment modality on chronic opioid use following treatment for head and neck cancer. Otolaryngol Head Neck Surg. 2021;164:799-806.
29.
BolligCAJorgensenJB.Effect of treatment modality on chronic opioid use in patients with T1/T2 oropharyngeal cancer. Head Neck. 2019;41(4):892-898.
30.
TrottiABellmLAEpsteinJB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253-262.
31.
KriplaniALaveryJAMishraA, et al. Trends in chronic opioid therapy among survivors of head and neck cancer. Head Neck. 2021;43(1):223-228.
32.
SaraswathulaAChenMMMudumbaiSCWhittemoreASDiviV.Persistent postoperative opioid use in older head and neck cancer patients. Otolaryngol Head Neck Surg. 2019;160(3):380-387.
33.
Adjei BoakyeEJohnstonKJMoulinTA, et al. Factors associated with head and neck cancer hospitalization cost and length of Stay-A national study. Am J Clin Oncol. 2019;42(2):172-178.
34.
PenelNMalletYRoussel-DelvallezMLefebvreJLYazdanpanahY.Factors determining length of the postoperative hospital stay after major head and neck cancer surgery. Oral Oncol. 2008;44(6):555-562.
35.
HahJMBatemanBTRatliffJCurtinCSunE.Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. Anesth Analg. 2017;125(5):1733-1740.
36.
JiangXOrtonMFengR, et al. Chronic opioid usage in surgical patients in a large academic center. Ann Surg. 2017;265(4):722-727.
37.
DowellDHaegerichTMChouR.CDC guideline for prescribing opioids for chronic pain—united States, 2016. JAMA. 2016;315(15):1624-1645.
38.
ShahAHayesCJMartinBC.Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66:265-269.
39.
DunnLKDurieuxME.Perioperative use of intravenous lidocaine. Anesthesiology. 2017;126:729-737.
40.
DuEFarzalZStephensonE, et al. Multimodal analgesia protocol after head and neck surgery: effect on opioid use and pain control. Otolaryngol Head Neck Surg. 2019;161(3):424-430.
41.
CramerJDBarnettMLAnneS, et al. Nonopioid, multimodal analgesia as first-line therapy after Otolaryngology operations: primer on nonsteroidal anti-inflammatory drugs (NSAIDs). Otolaryngol Head Neck Surg. 2021;164:712-719.
42.
LeeTSWangLLYiDIPrasannaPDKandlC.Opioid sparing multimodal analgesia treats pain after head and neck microvascular reconstruction. Laryngoscope. 2020;130(7):1686-1691.
43.
DortJCFarwellDGFindlayM, et al. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society. Otolaryngol Head Neck Surg. 2017;143(3):292-303.
